Record Details

Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects

Farmeconomia

View Archive Info
 
 
Field Value
 
Title Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects
 
Creator Lazzaro, Carlo
 
Subject Pharmacoeconomics; Health economics
Telitromicin; Clarithromycin; CAP; AECB; Cost-minimization analysis
 
Description The aim of the paper is to compare Italian healthcare-related costs and effectiveness of 7- and 5- day course with telitromicin (Ketek®) 800 mg od vs. 10-day clarithromycin 500 mg bid in patients with Community-acquired pneumonia (CAP) and Acute exacerbations of chronic bronchitis (AECB), respectively. Clinical as well as healthcare-related resource consumption data were collected from two Medline indexed articles reporting results of three international trials. Since differences in effectiveness among the compared antibiotic courses did not reach statistical significance, two cost-minimization analyses were performed from Italian National Healthcare Service (INHS) perspective. CAP and AECB-related hospitalizations were evaluated according to INHS DRGs tariffs, whereas drugs were costed according to Italian National Therapeutic Formulary. Costs are expressed in euros 2005. When compared to 10-day clarithromycin 500 mg bid, savings related to 7-day telitromicin 800 mg od approach 102,10 euros per CAP patient (IC 95: -177,89 euros − -26,31 euros; p
 
Publisher SEEd Medical Publishers
 
Date 2006-09-15
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format application/pdf
 
Identifier https://journals.edizioniseed.it/index.php/FE/article/view/679
10.7175/fe.v7i2.679
 
Source Farmeconomia. Health economics and therapeutic pathways; Vol 7, No 2 (2006); 89-96
2240-256X
1721-6915
 
Language eng
 
Relation https://journals.edizioniseed.it/index.php/FE/article/view/679/791
 
Rights Copyright (c) 2006 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0